834 related articles for article (PubMed ID: 34588146)
21. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer.
Patel S; Demanes DJ; Ragab O; Zhang M; Veruttipong D; Nguyen K; Park SJ; Marks L; Pantuck A; Steinberg M; Kamrava M
Brachytherapy; 2017; 16(2):299-305. PubMed ID: 27965117
[TBL] [Abstract][Full Text] [Related]
22. Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer.
Koontz BF; Chino J; Lee WR; Hahn CA; Buckley N; Huang S; Kim J; Reagan R; Joyner R; Anscher MS
Brachytherapy; 2009; 8(2):191-196. PubMed ID: 19433320
[TBL] [Abstract][Full Text] [Related]
23. Brachytherapy boost (BT-boost) or stereotactic body radiation therapy boost (SBRT-boost) for high-risk prostate cancer (HR-PCa).
Peyraga G; Lizee T; Khalifa J; Blais E; Mauriange-Turpin G; Supiot S; Krhili S; Tremolieres P; Graff-Cailleaud P
Cancer Radiother; 2021 Jun; 25(4):400-409. PubMed ID: 33478838
[TBL] [Abstract][Full Text] [Related]
24. Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience.
Chen LN; Suy S; Uhm S; Oermann EK; Ju AW; Chen V; Hanscom HN; Laing S; Kim JS; Lei S; Batipps GP; Kowalczyk K; Bandi G; Pahira J; McGeagh KG; Collins BT; Krishnan P; Dawson NA; Taylor KL; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2013 Mar; 8():58. PubMed ID: 23497695
[TBL] [Abstract][Full Text] [Related]
25. Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer.
Spratt DE; Zumsteg ZS; Ghadjar P; Kollmeier MA; Pei X; Cohen G; Polkinghorn W; Yamada Y; Zelefsky MJ
BJU Int; 2014 Sep; 114(3):360-7. PubMed ID: 24447404
[TBL] [Abstract][Full Text] [Related]
26. Biochemical Control and Toxicity Outcomes of Stereotactic Body Radiation Therapy Versus Low-Dose-Rate Brachytherapy in the Treatment of Low- and Intermediate-Risk Prostate Cancer.
Gogineni E; Rana Z; Soberman D; Sidiqi B; D'Andrea V; Lee L; Potters L; Parashar B
Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1232-1242. PubMed ID: 33171199
[TBL] [Abstract][Full Text] [Related]
27. Low-Dose-Rate Brachytherapy Combined With Ultrahypofractionated Radiation Therapy for Clinically Localized, Intermediate-Risk Prostate Cancer: Results From a Prospective Trial.
Kollmeier MA; McBride S; Varghese M; Debonis D; Zhang Z; Cohen G; Damato AL; Mychalczak B; Gewanter R; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):905-913. PubMed ID: 32505609
[TBL] [Abstract][Full Text] [Related]
28. Dose-Escalated Stereotactic Body Radiation Therapy for Patients With Intermediate- and High-Risk Prostate Cancer: Initial Dosimetry Analysis and Patient Outcomes.
Kotecha R; Djemil T; Tendulkar RD; Reddy CA; Thousand RA; Vassil A; Stovsky M; Berglund RK; Klein EA; Stephans KL
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(3):960-964. PubMed ID: 27302511
[TBL] [Abstract][Full Text] [Related]
29. Ten-Year Outcomes of Moderately Hypofractionated (70 Gy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer.
Abu-Gheida I; Reddy CA; Kotecha R; Weller MA; Shah C; Kupelian PA; Mian O; Ciezki JP; Stephans KL; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):325-333. PubMed ID: 30721720
[TBL] [Abstract][Full Text] [Related]
30. A Multicenter Phase 2 study of Hypofractionated Stereostatic Boost in Intermediate Risk Prostate Carcinoma: A 5-Year Analysis of the CKNO-PRO Trial.
Pasquier D; Peiffert D; Nickers P; Maingon P; Pommier P; Lacornerie T; Martinage G; Tresch E; Lartigau E
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):116-123. PubMed ID: 31604131
[TBL] [Abstract][Full Text] [Related]
31. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
Baumann BC; Baumann JC; Christodouleas JP; Soffen E
Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
[TBL] [Abstract][Full Text] [Related]
32. Ultra-hypofractionated radiotherapy for low- and intermediate risk prostate cancer: High-dose-rate brachytherapy vs stereotactic ablative radiotherapy.
Tsang YM; Tharmalingam H; Belessiotis-Richards K; Armstrong S; Ostler P; Hughes R; Alonzi R; Hoskin PJ
Radiother Oncol; 2021 May; 158():184-190. PubMed ID: 33639192
[TBL] [Abstract][Full Text] [Related]
33. Quality-of-Life Outcomes and Toxicity Profile Among Patients With Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multicenter Phase 2 Trial.
Ma TM; Ballas LK; Wilhalme H; Sachdeva A; Chong N; Sharma S; Yang T; Basehart V; Reiter RE; Saigal C; Chamie K; Litwin MS; Rettig MB; Nickols NG; Yoon SM; Smith L; Gao Y; Steinberg ML; Cao M; Kishan AU
Int J Radiat Oncol Biol Phys; 2023 Jan; 115(1):142-152. PubMed ID: 36007724
[TBL] [Abstract][Full Text] [Related]
34. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G
Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509
[TBL] [Abstract][Full Text] [Related]
35. Does the sequence of high-dose rate brachytherapy boost and IMRT for prostate cancer impact early toxicity outcomes? Results from a single institution analysis.
Roy A; Brenneman RJ; Hogan J; Barnes JM; Huang Y; Morris R; Goddu S; Altman M; Garcia-Ramirez J; Li H; Zoberi JE; Bullock A; Kim E; Smith Z; Figenshau R; Andriole GL; Baumann BC; Michalski JM; Gay HA
Clin Transl Radiat Oncol; 2021 Jul; 29():47-53. PubMed ID: 34136665
[TBL] [Abstract][Full Text] [Related]
36. Early Tolerance and Tumor Control Outcomes with High-dose Ultrahypofractionated Radiation Therapy for Prostate Cancer.
Zelefsky MJ; Pinitpatcharalert A; Kollmeier M; Goldman DA; McBride S; Gorovets D; Zhang Z; Varghese M; Happersett L; Tyagi N; Hunt M
Eur Urol Oncol; 2020 Dec; 3(6):748-755. PubMed ID: 31668713
[TBL] [Abstract][Full Text] [Related]
37. External Beam Radiation Therapy (EBRT) and High-Dose-Rate (HDR) Brachytherapy for Intermediate and High-Risk Prostate Cancer: The Impact of EBRT Volume.
Tharmalingam H; Tsang Y; Choudhury A; Alonzi R; Wylie J; Ahmed I; Henry A; Heath C; Hoskin PJ
Int J Radiat Oncol Biol Phys; 2020 Mar; 106(3):525-533. PubMed ID: 31610249
[TBL] [Abstract][Full Text] [Related]
38. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients.
Levin-Epstein R; Cook RR; Wong JK; Stock RG; Jeffrey Demanes D; Collins SP; Aghdam N; Suy S; Mantz C; Katz AJ; Nickols NG; Miszczyk L; Napieralska A; Namysl-Kaletka A; Prionas ND; Bagshaw H; Buyyounouski MK; Cao M; Mahal BA; Shabsovich D; Dang A; Yuan Y; Rettig MB; Chang AJ; Jackson WC; Spratt DE; Lehrer EJ; Zaorsky NG; Kupelian PA; Steinberg ML; Horwitz EM; Jiang NY; Kishan AU
Radiother Oncol; 2020 Oct; 151():26-32. PubMed ID: 32663537
[TBL] [Abstract][Full Text] [Related]
39. Outcomes Associated With 3 Treatment Schedules of High-Dose-Rate Brachytherapy Monotherapy for Favorable-Risk Prostate Cancer.
Jawad MS; Dilworth JT; Gustafson GS; Ye H; Wallace M; Martinez A; Chen PY; Krauss DJ
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):657-66. PubMed ID: 26797541
[TBL] [Abstract][Full Text] [Related]
40. Combined Low Dose Rate Brachytherapy and External Beam Radiation Therapy for Intermediate-Risk Prostate Cancer.
Chao M; Joon DL; Khoo V; Spencer S; Ho H; Guerrieri M; Foroudi F; Bolton D
J Med Imaging Radiat Sci; 2019 Mar; 50(1):82-86. PubMed ID: 30777253
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
